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Abstract 20 
The two major isoforms of the oncogenic Bcr-Abl tyrosine kinase, p210 and p190, 21 
are expressed upon the Philadelphia chromosome translocation. p210 is the 22 
hallmark of chronic myelogenous leukemia, whereas p190 occurs in the majority 23 
of B-cell acute lymphoblastic leukemia. Differences in protein interactions and 24 
activated signaling pathways that may be associated with the different diseases 25 
driven by p210 and p190 are unknown. We have performed a quantitative 26 
comparative proteomics study of p210 and p190. Strong differences in the 27 
interactome and tyrosine phosphoproteome were found and validated. Whereas 28 
the AP2 adaptor complex that regulates clathrin-mediated endocytosis interacts 29 
preferentially with p190, the phosphatase Sts1 is enriched with p210. Stronger 30 
activation of the Stat5 transcription factor and the Erk1/2 kinases is observed 31 
with p210, whereas Lyn kinase is activated by p190. Our findings provide a more 32 
coherent understanding of Bcr-Abl signaling, mechanisms of leukemic 33 
transformation, resulting disease pathobiology and responses to kinase inhibitors. 34 
35 
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Introduction 36 
The Bcr-Abl kinase and its inhibitors (imatinib and successors) are a paradigm 37 
for targeted cancer therapy1. Bcr-Abl is a constitutively active tyrosine kinase, 38 
expressed by the Philadelphia (Ph) chromosome. It is formed upon the t(9;22) 39 
reciprocal translocation that fuses the breakpoint cluster region (BCR) gene with 40 
the Abelson tyrosine kinase (ABL1)2. Depending on the translocation breakpoint 41 
in BCR, different Bcr-Abl protein isoforms are expressed, which all contain exons 42 
2-11 of the ABL1 gene, but differ in the length of their BCR component3. The 43 
most common Bcr-Abl isoforms are p210 and p190 (alternatively named: p185). 44 
p190 is 501 amino acids, i.e. ~25%, shorter than p210 because it lacks a DH-PH 45 
domain unit; otherwise p210 and p190 have an identical sequence and domain 46 
organization (Fig. 1a)4. 47 
The expression of p210 is the molecular hallmark of chronic myelogenous 48 
leukemia (CML)3. The Ph-chromosome is also present in 20-30% of adult B-cell 49 
acute lymphoblastic leukemias (B-ALL), where approximately 1/4 of these 50 
patients express p210 and approximately 3/4 express p190 Bcr-Abl3. Treating 51 
CML patients with the Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib leads to 52 
durable remissions in most patients and the survival of those patients is not 53 
different from that of the general population5. In contrast, in Ph-positive B-ALL, 54 
relapse and TKI resistance are frequent, and overall survival is still dramatically 55 
low, despite the increased remission rates and survival that can be achieved with 56 
Bcr-Abl TKIs6,7. 57 
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p210 is the sole oncogenic driver that is sufficient to establish and maintain CML. 58 
In contrast, in Ph-positive B-ALL, additional mutations are frequently observed8. 59 
Various mouse models that express Bcr-Abl in hematopoietic stem cells or 60 
progenitor cells were developed and recapitulate many features of human CML 61 
and B-ALL9,10. Only a few studies have compared the in vivo leukemogenic 62 
activity of p190 and p210 directly. Under specific experimental conditions, the 63 
expression of p190 lead to a disease with a shorter latency and more B-ALL, 64 
whereas p210 mice developed CML-like leukemias11,9,12,13. This may argue that 65 
the specific intrinsic differences in the p190 and p210 proteins contribute to the 66 
two different disease pathologies, in addition to the described different cell-of-67 
origin of the observed p210 and p190-driven leukemias12. Differences in activity 68 
and signaling between p210 and p190 have long been hypothesized but never 69 
studied in a comprehensive and quantitative manner. Early studies on selected 70 
signaling molecules indicated that qualitatively the same pathways are activated 71 
by p210 and p19014, whereas kinase assays tended towards a mildly higher 72 
kinase activity for p19011,15,16. The p210 interaction network has been mapped by 73 
affinity purification mass spectrometry experiments with p210 interactors as baits 74 
using non-quantitative proteomics17,18. To date, very little is known regarding 75 
specific protein interaction partners and substrates of p190, and most importantly, 76 
the two Bcr-Abl isoforms have not been compared directly in a uniform cellular 77 
background. 78 
Being aware of the large amount, but heterogeneous data regarding Bcr-Abl 79 
interacting proteins and activated downstream pathways, we performed a first 80 
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comparative, quantitative and systematic proteomics study to chart the common 81 
and differential interactome and tyrosine phosphoproteome of p210 and p190 82 
Bcr-Abl. We show that the differences in interactome and phosphoproteome of 83 
p210 and p190 are surprisingly large despite similar kinase activation. Our study 84 
provides the first consolidated view on oncogene-intrinsic signaling differences of 85 
p210 and p190 in a defined cellular background. 86 
 87 
Materials and Methods 88 
Interactome sample preparation 89 
The optimized final protocol used 80-100 mg total cell lysate per cell line, 90 
corresponding to approx. 7-10*108 BaF3 cells. Cell lysis and purification was 91 
performed in TAP buffer (50 mM TRIS pH 7.5, 100 mM NaCl, 5% glycerol, 92 
0.2% (w/v) NP-40 Alternative) containing protease and phosphatase inhibitors 19. 93 
Normal mouse IgG antibody (Thermo Scientific, catalog no. 10400C) and the 94 
monoclonal Abl antibody (clone 24-21)20 were covalently coupled to NHS-95 
activated sepharose (GE Healthcare, catalogue no. 17-0906-01). The lysates 96 
were pre-cleared for 1 h at 4°C with the IgG-NHS resin and the supernatant then 97 
transferred to the Abl-NHS resin for another 3 h at 4°C. Elution fractions 98 
containing Bcr-Abl were pooled prior to mixing of the three individual 99 
immunoprecipitates of BaF3 parental, p210 and p185 with equal volumes and 100 
subsequently lyophilized.  101 
 102 
Phosphoproteome sample preparation 103 
 
 
 6
Cell lysis was accomplished in Urea buffer (8 M Urea, 50 mM Hepes, pH 7.6) 104 
using 2 mL buffer for 1*108 cells. 10 mg of total cell lysate of each sample (light, 105 
medium and heavy labeled) were mixed to have a final amount of 30 mg SILAC 106 
sample for peptide preparation. Phosphotyrosine peptides were enriched using a 107 
mixture of two phosphotyrosine antibodies: The pY1000 antibody that is part of 108 
the PTMScan® Phospho-Tyrosine Rabbit mAb (P-Tyr-1000) Kit (Cell Signaling 109 
Technologies, catalogue number 8803), in addition to 50 µL NHS-coupled 4G10 110 
antibody. For the pY eluates, a second step of phosphopeptide enrichment was 111 
performed on TiO2 tips as described21 prior MS analysis. 112 
 113 
Data Analysis and MS raw data 114 
A detailed description of the mass spectrometry data analysis to identify 115 
differential hits is given in Supplementary Information. Detailed lists of all 116 
interactors and phosphosites are provided in Supplementary Tables S4-S8 and 117 
an annotated Excel file with complete data. In addition, the mass spectrometry 118 
proteomics data have been deposited to the ProteomeXchange Consortium via 119 
the PRIDE partner repository with the dataset identifier PXD00514922. 120 
 121 
A detailed description of the methods used in this study is given in the 122 
Supplementary Methods. 123 
 124 
Results 125 
Bcr-Abl interactome analysis 126 
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To identify and quantify the protein interaction network of p210 and p190 Bcr-Abl, 127 
we used a quantitative proteomics workflow based on SILAC (stable isotope 128 
labeling with amino acids in cell culture; Fig. 1b). Murine BaF3 cells that express 129 
Abl endogenously were retrovirally transduced with the human Bcr-Abl p210 and 130 
p190 cDNAs23 and purification of Bcr-Abl complexes was achieved by 131 
immunoprecipitation (IP) experiments using an immobilized anti-Abl antibody 132 
with 80-100 mg of total protein lysate in biological duplicates. Parental 133 
(untransduced) BaF3 cells were used as a control to distinguish (endogenous) 134 
Abl from Bcr-Abl interactors (Fig. 1b, Supplementary Table S1). We achieved the 135 
quantification of >1800 proteins and a strong enrichment of Bcr-Abl p210 and 136 
p190 complexes over the parental control (Fig. 2a, Supplementary Fig. S1a,b). 137 
Furthermore, we identified most of the previously suggested p210 core 138 
interactors17, which we found to be enriched with Bcr-Abl compared to the 139 
parental control (Supplementary Fig. S1a, b). 140 
To subsequently identify common Bcr-Abl interactors and proteins that 141 
preferentially or exclusively interact with either p210 or p190, we first identified 142 
proteins that are enriched in either p210 or p190 Bcr-Abl samples compared to 143 
the parental control (Fig. 2b). This strategy removed Abl interacting and 144 
contaminating proteins from further analysis. To compensate for the differential 145 
expression levels in the three different cell lines, we normalized the protein ratios 146 
for the input amounts, where ~4000 proteins of the expressed total proteome 147 
could be quantified (Fig. 2b). The resulting 147 proteins included 56 proteins that 148 
were common to both Bcr-Abl isoforms (defined as common Bcr-Abl interactors; 149 
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Supplementary Table S4), 30 proteins that were only found in the p210 samples 150 
and 59 proteins in the p190 samples (Fig. 2b). The excellent sequence coverage 151 
from the Bcr-Abl region common to p210 and p190 allowed a precise 152 
quantification of and subsequent correction for the Bcr-Abl bait amount in the 153 
large-scale IP samples (Supplementary Fig. S1c, d). For the comparison of the 154 
p210 and p190 interactors, this correction step is essential, because higher 155 
amounts of Bcr-Abl bait protein in one of the samples would lead to an 156 
overestimation of the amount of interactor. In both biological replicates p210 was 157 
~1.4-fold enriched over p190 based on the mass spectrometry quantification (Fig. 158 
2b, Supplementary Fig. S1c, d). After these normalization steps, we 159 
concentrated on those proteins that were at least 2-fold enriched, with 13 160 
proteins for p210 and 34 proteins for p190 (Fig. 2c, Supplementary Table S5).  161 
 162 
Common Bcr-Abl interactors 163 
Among the 56 common Bcr-Abl interactors (Fig. 3, Supplementary Table S4), 164 
network analysis using the STRING database (http://string-db.org/) showed 165 
previously annotated experimentally determined interactions between the 166 
majority of these proteins. Only 15 molecules remain without previously mapped 167 
interactions (Supplementary Fig. S2a). Two major clusters were identified with 168 
one sub-network covering many cytosolic signaling components from tyrosine 169 
kinase and Ras-MAPK signaling pathways. These proteins include prototypic 170 
signaling adaptors (Grb2, Shc1, Dok1, Gab2), E3 ubiquitin ligases (Cbl, Cblb), 171 
phosphatases (Inppl1/Ship2 and Ptpn11/Shp2), kinases (Map4k1, Lrrk1), 172 
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GTPase effector proteins (including the Ras GEFs Sos1/2) and cytoskeleton 173 
remodeling proteins (e.g., the Abi1-Wasf2-Cyfip2 complex), which is also 174 
reflected in the KEGG pathway and GO term enrichment (Supplementary Fig. S2, 175 
Fig. 3). The three most significantly enriched domains using the SMART 176 
database were the SH2, SH3 and PH domains.  177 
The very tightly interconnected second sub-network contained the tetrameric 178 
adaptor protein complex 2 (AP2), of which all four subunits were identified, with 179 
various associated proteins that play a key role in regulating clathrin-mediated 180 
endocytosis of receptor proteins and other membrane trafficking processes (Fig. 181 
3). In addition to these two clusters, a small group of proteins with no previously 182 
experimentally mapped connections is included in the network of common Bcr-183 
Abl interactors, such as the kinase co-chaperone Cdc37 and two members of the 184 
14-3-3 proteins (Ywhag and Ywhah) (Fig. 3). 185 
Notably, there is a large overlap of the mapped common Bcr-Abl interactors with 186 
the previously identified p210 Bcr-Abl interactors using non-quantitative 187 
proteomics by affinity purification mass spectrometry of known Bcr-Abl 188 
interacting adaptor proteins in either the human K562 cell line17 or BaF3 cells18. 189 
Due to the use of SILAC, we achieve accurate quantitation and unbiased 190 
analyses. 191 
 192 
Preferential and exclusive interactors of p210 and p190 193 
The proteins that were differentially quantified between the two Bcr-Abl isoforms 194 
partly belong to the group of common Bcr-Abl interactors (preferential 195 
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interactors), whereas another fraction of proteins is exclusive to one of the Bcr-196 
Abl isoforms and not part of the common Bcr-Abl interactome. With regard to 197 
p190 Bcr-Abl, 17 of the 34 identified proteins are also part of the common 198 
interactors including most of the AP2 complex members and the Nck2 (SH3/SH2 199 
adaptor)-Rasa1 (Ras GAP)-Lyn (Src family tyrosine kinase) complex. The 200 
remaining 17 proteins are only found in p190 and include additional members of 201 
the endocytosis machinery, such as the clathrin light and heavy chains (Cltca/b/c) 202 
(Fig. 3, Supplementary Fig. S2 and Table S5).  203 
Conversely, 3 of the 13 proteins that differentially bind to p210, are also part of 204 
the common Bcr-Abl interactors (Ubash3b/Sts1, Bcr and Shank3; Fig. 3, 205 
Supplementary Table S5). In contrast to p190, the differential proteins for p210 206 
have no annotated experimental evidence for interaction with each other. 207 
Remarkably, the non-canonical tyrosine phosphatase Ubash3b/Sts1 shows a 208 
mean 6.5-fold enriched interaction with p210 Bcr-Abl (Fig. 2c). 209 
 210 
Interactome target validation 211 
Validation of the interactome data was conducted by immunoblot analysis of the 212 
SILAC samples used for the MS analysis as an independent analytical method. 213 
Furthermore, anti-Abl immunoprecipitations were conducted for a set of human 214 
p210 and p190 expressing cell lines that were derived from CML and B-ALL 215 
patients (Supplementary Table S3, Supplementary Figure S3). In addition, an 216 
independent set of BaF3 p210 and p190 cells was created and used as a further 217 
control. 218 
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We first focused on the tyrosine phosphatase Sts1 that was found as a common 219 
Bcr-Abl interactor and greatly enriched with p210 Bcr-Abl. The enrichment was 220 
confirmed in the immunoblot analysis of the SILAC samples (Fig. 2d) and the 221 
independent BaF3 set (Supplementary Fig. S3). For the human cell lines a less 222 
pronounced preference of Sts1 for p210 was observed (Supplementary Fig. S3). 223 
The interpretation of such experiments is severely challenged by the different 224 
Bcr-Abl and interactor expression levels in the human cell lines (Supplementary 225 
Fig. S3c), as well as the different cellular proteome background of the cells. 226 
Validation of proteins that were enriched with p190 included Ap2a1/2, which is a 227 
subunit of the tetrameric AP2 complex, and the protein tyrosine kinase Lyn. 228 
Immunoblot analysis of the SILAC samples confirmed the findings by mass 229 
spectrometry (Fig. 2d). The validation of Lyn in the human cell lines was 230 
complicated by limited antibody sensitivity and differential antibody binding to 231 
human and mouse Lyn, but with a possible trend towards p190 (Supplementary 232 
Fig. S3). Nonetheless, this data is nicely in line with several Lyn tyrosine sites 233 
that are stronger phosphorylated in p190 cells.  234 
Among the common interactors of p210 and p190, we validated the Inppl1/Ship2 235 
interaction. Although the Ship2 antibody surprisingly did not recognize the mouse 236 
form of the protein, the human cells showed uniform interactions of Ship2 with 237 
p210 or p190 (Supplementary Fig. S3). 238 
In conclusion, we found and validated intriguingly strong differences in the 239 
protein interaction network of p210 and p190. Interestingly, our dataset shows a 240 
number of proteins preferentially interacting with p190, even though the longer 241 
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isoform p210 contains the additional DH-PH domains. Our data thus suggests 242 
that the DH-PH domain does not act as a protein-interaction scaffold. 243 
Alternatively, a different degree of kinase activation could result in rewiring of the 244 
cellular signaling network and thus change Bcr-Abl interaction partners. 245 
 246 
Analysis of phosphorylation sites and activity of p210 and p190 Bcr-Abl 247 
To test our hypothesis of possible quantitative differences in p210 and p190 248 
activation, we studied the kinase activation state of Bcr-Abl by mapping 249 
phosphorylation sites by mass spectrometry, immunoblotting for major activating 250 
phosphorylation sites, and in vitro kinase activity assays. 251 
We could quantify 17 tyrosine phosphorylation sites of Bcr-Abl by mass 252 
spectrometry (Fig. 4a). As expected, the five tyrosine phosphorylation sites 253 
(Y554, Y644, Y844, Y852 and Y910) that are unique to the p210 sequence were 254 
found strongly enriched in the p210 sample. In contrast, Y177 was 255 
phosphorylated to almost identical levels in p210 and p190, in line with our 256 
interactome data showing equal amounts of Grb2, which binds Y177 via its SH2 257 
domain (Fig. 4a). For the remaining Bcr-Abl phosphorylation sites, including 258 
Y412 in the activation loop and Y245, both commonly used Bcr-Abl activation 259 
markers24, insignificant differences were observed (Fig. 4a). In parallel, we 260 
monitored the phosphorylation state of Y412 and Y245 by immunoblotting using 261 
the total cell lysates of the SILAC samples and the human cell lines. Whereas 262 
the BaF3 cells show a slight increase of pY245 in the p210 cells, there is no 263 
major difference for pY412 between the isoforms (Fig. 4b,c). The human cell 264 
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lines, albeit quite heterogeneous, revealed a higher tendency of both 265 
phosphorylation sites towards p210 (Fig. 4b,c). Similar results were obtained 266 
when equal amounts of Bcr-Abl after immunoprecipitation were loaded to 267 
facilitate normalization (Supplementary Fig. S4). 268 
We next compared the Bcr-Abl in vitro kinase activity after anti-Abl 269 
immunoprecipitation from BaF3 and our panel of eight human cell lines. We 270 
observed only minor differences without a consistent trend towards higher in vitro 271 
kinase activity of one of the two Bcr-Abl isoforms (Fig. 4d). We additionally 272 
probed global p210 and p190 kinase activity using the PamChip PTK assay 273 
(PamGene). We observed only minor differences between the samples with only 274 
7 of the 142 peptides phosphorylated stronger by the p210 lysate 275 
(Supplementary Fig. S5) in contrast to a previous study in which we compared 276 
Nup214-Abl and p210 activity in BaF3 cells25. 277 
Collectively, our data suggest that p210 and p190 do not differ significantly in 278 
kinase autophosphorylation or in vitro kinase activity. These results argue 279 
against quantitative differences in kinase activation may account for the 280 
observed differences in the p210 vs. p190 interactome and phosphoproteome. 281 
 282 
Bcr-Abl phosphoproteome analysis 283 
In addition to the phosphotyrosine sites of Bcr-Abl, we mapped the cellular 284 
tyrosine phosphoproteome and quantified 817 phosphotyrosine sites in 573 285 
protein groups (Fig. 5a, Supplementary Fig. S6). Unsupervised hierarchical 286 
clustering of the quantified phosphopeptides revealed six clusters with cluster 1 287 
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comprising all the sites that remained unchanged among the three cell lines (Fig. 288 
5a). Clusters 2, 3 and 4 depict the phosphopeptides that are up-regulated in the 289 
Bcr-Abl cell lines compared to the parental cell line. Here in particular, clusters 2 290 
and 3 (with 302 phosphopeptides corresponding to 37% of all quantified pY 291 
peptides) stood out due to the high intensity of phosphorylation as compared to 292 
the BaF3 parental cells, thus representing the Bcr-Abl pY signature (Fig. 5a). 293 
Among those peptides, 45 sites map to 27 of the Bcr-Abl interacting proteins 294 
identified in the interactome study, which makes it the cluster with the largest 295 
accumulation of Bcr-Abl interactors (Supplementary Fig. S7). In-depth analysis of 296 
the phosphosites within this cluster revealed many known and amply 297 
characterized substrates of Bcr-Abl such as Abi1, Cbl, Gab2, Pik3r1, Pxn 298 
(paxillin) and Stat526 that is also reflected in the GO term enrichment analysis of 299 
these proteins containing CML and other tyrosine kinase signaling pathways 300 
(Supplementary Fig. S7). In addition, phosphomotif analysis showed enrichment 301 
of the Abl phosphorylation site consensus in cluster 2 and 3 (67 out of 273 302 
unique peptides) with a proline in position +3 following the phosphorylated 303 
tyrosine (Supplementary Fig. S7). Altogether, our dataset indicated that the 304 
mapped tyrosine phosphoproteome is dominated by Bcr-Abl kinase signaling 305 
and included many known substrates and phosphorylated interactors (Fig. 3). 306 
 307 
Differential phosphorylation sites of p210 and p190 308 
The analysis of differential p210 and p190 phosphorylation events resulted in 309 
106 pY sites in 78 proteins to be more highly phosphorylated in p190, 110 pY 310 
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sites in 92 proteins to be more highly phosphorylated in p210 (Fig. 5b and 311 
Supplementary Table S6 and S7).  312 
Among the sites up-regulated in p210, 6 phosphorylation sites of the 313 
transcription factor Stat5a and Stat5b were mapped, including the main site 314 
responsible for Stat5a activation (Y694 in Stat5a, Fig. 6, Supplementary Table 315 
S7)27. In addition, the activation loops of the tyrosine kinase Fes (Y713) and the 316 
Ser/Thr-kinases Erk1 (Y205) and Erk2 (Y185) and sites of the Src family kinases 317 
Fyn (Y185) and Lck (Y192), were found to be more highly phosphorylated (Fig. 318 
6). This indicated a higher activation of these kinases in the p210 expressing 319 
cells. The high number of kinases that are phosphorylated in the p210 sample is 320 
also reflected in the GO term and KEGG pathway enrichment analysis 321 
(Supplementary Fig. S7). 322 
Among the 106 pY sites up-regulated in p190, 6 phosphosites of the Src family 323 
tyrosine kinase Lyn (two of which shared with Blk), including its activation loop 324 
(Y397) were found to be more strongly phosphorylated than in p210 (Fig. 6). This 325 
is nicely in line with the stronger interaction of Lyn with p190 than p210 (Fig. 2c). 326 
In addition the non-receptor tyrosine phosphatases Shp2 (Ptpn11) and Flk1 327 
(Ptpn18) showed higher phosphorylation in p190 cells, which may indicate a 328 
stronger activation of these enzymes in p190 cells. Furthermore, we found the 329 
adapter proteins Dok1 and Pag1 to be more highly phosphorylated in p190, and 330 
they, together with Ptpn11 and Ptpn18 were shown to play a central role in the 331 
negative feedback regulation of Src family kinases (Fig. 6)28. 332 
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Noteworthy, among the 552 pY sites that remain unchanged between the two 333 
Bcr-Abl isoforms, we found many central signaling molecules mediating pY 334 
signaling (Supplementary Table S8). These included adaptor proteins (CrkL, 335 
Shc1, Gab2, Nck1/2, Abi1/2, Dok1/2/3, Sh2d3/5, Skap2, several 14-3-3 336 
isoforms), E3 ubiquitin ligases (Cbl, Cblb), lipid and protein phosphatases 337 
(Inppl1/5d, Ptpn6, Ptprc, Ptprj), several PI3-kinase subunits and the transcription 338 
factor Stat6. In addition, a large number of activating pY sites on cytoplasmic 339 
tyrosine kinases (Btk, Tec, Jak2, Csk, Tnk2, Syk) as well as serine/threonine 340 
kinases (Cdk1/17, Mapk14/11/12 = p38α/β/γ, Sgk233, Map4k1, Pkcδ) were 341 
found (Fig. 6 and Supplementary Table S8). This shows the large deregulation of 342 
cellular signaling by Bcr-Abl and its link to core proliferative and anti-apoptotic 343 
pathways that sustain leukemogenesis. Collectively, our analysis identified many 344 
differentially regulated phosphosites with annotated functional importance along 345 
with a large number of functionally uncharacterized sites in important signaling 346 
proteins. 347 
 348 
Phosphoproteome site validation 349 
Validation of the phosphoproteomic dataset was conducted by immunoblot 350 
analysis of the SILAC samples in addition to the set of human p210 and p190 351 
Bcr-Abl expressing cell lines (Supplementary Table S3). Among the 6 up-352 
regulated Stat5a/b phosphorylation sites in p210, we concentrated on 353 
Y694/Y695 in Stat5a/b, since it is the major activating site. We could confirm the 354 
MS results in BaF3 and human CML cell lines (Fig. 5c, d). In line with the 355 
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analysis of the total BaF3 Stat5 protein amount by MS, we also observed 356 
elevated Stat5 expression levels in p210 expressing cells. Nonetheless, pStat5 357 
levels were increased also after correction for the elevated total protein levels 358 
showing increased Stat5 phosphorylation stoichiometry in p210 cells (Fig. 5c, d). 359 
Another member of the Stat transcription factors, Stat3, also showed elevated 360 
phosphorylation on the main activating site (Y704) in p210 in line with the MS 361 
results (Supplementary Fig. S8). In contrast, we found Stat6 to be equally 362 
phosphorylated on its main activating site (Y641; Fig. 6) 363 
Src family kinases were found phosphorylated in both Bcr-Abl cell lines with Lyn 364 
being activated in p190 cells, and Fyn and Lck phosphorylation being higher in 365 
p210 cells. Due to the high sequence homology within this kinase family, 366 
antibodies for the activation loop of Src kinases cannot distinguish the different 367 
kinases of this family. Nonetheless, we attempted to monitor pSrc levels in our 368 
cell lines and found higher general pSrc levels in BaF3 p190 cells compared to 369 
the human cell lines, in which we observed a trend towards higher pSrc levels in 370 
the p210 Bcr-Abl cells (Supplementary Figure S8). A clear interpretation of this 371 
data is difficult, as the human cell lines have strongly different Src kinase 372 
expression patterns and levels. Therefore, reliable normalization of the pSrc 373 
signal is impossible. Interestingly, tyrosine kinase prediction based on the 374 
analysis of the PamChip PTK assay indicated overall stronger activation of Src 375 
kinases in p210 cells (Supplementary Fig S5). In contrast, we used an antibody 376 
that is specific for the C-terminal inhibitory phosphorylation site of Lyn (Y507) 377 
because we found several proteins of the Src negative-feedback circuit 378 
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phosphorylated in p190. Immunoblot analysis showed higher levels of pY507 379 
phosphorylation in Bcr-Abl expressing BaF3 cells as compared to the parental 380 
cells but did not appear to differ between the two isoforms (Supplementary Fig. 381 
S8). The same was found for the human cell lines, where high levels of Lyn 382 
pY507 correlate with a high expression level.  383 
Kinase activity profiling on the PamChip STK assay (PamGene) revealed a much 384 
higher activity of Ser/Thr kinases in the lysate of p210 with more than 20% of the 385 
peptides being more phosphorylated as compared to the p190 lysate. The 386 
prediction of putative upstream kinases from these data suggested the 387 
involvement of Sgk2, Akt and Dclk2 (Supplementary Fig. S5).  388 
In summary, we found strongly activated Stat5 in p210, Dok1 in p190, and Src 389 
kinase members appear to be differentially activated by p210 and p190. In line 390 
with the observations of an isoform-dependent interactome, also the 391 
phosphoproteome varies significantly with the Bcr-Abl isoform and suggests 392 
important differential signaling nodes with possible therapeutic implications 393 
(Fig. 7). 394 
 395 
Discussion 396 
We observed many differences in both the interactome and the 397 
phosphoproteome between the two Bcr-Abl isoforms (Fig. 3 and 6). Because 398 
p190 can be considered as an internal deletion mutant of p210, lacking 501 399 
amino acids that encode for a DH-PH domain unit, significant gains in the p210 400 
interactome were expected rather than the observed balanced number of 401 
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interactors, excluding a scaffolding function of the DH-PH domain. This 402 
observation raises questions regarding the molecular mechanism. Our initial 403 
hypothesis on a different degree of kinase activity deregulation could be 404 
excluded. Even in BaF3 cells, i.e. in the same proteomic 'background', 405 
differences in kinase activation were insignificant. In line with this, the human cell 406 
lines also showed no consistent differences of p210 and p190 Bcr-Abl kinase 407 
activation. It is also unlikely to assume that the different length of the Bcr portion 408 
of p190 and p210 may change substrate specificity because the substrate 409 
binding groove in the kinase domain primarily determines the kinase substrate 410 
specificity, which is identical in p210 and p190. A second attractive hypothesis 411 
includes a possible differential subcellular localization that is caused by the 412 
different overall structure and domain composition of the two isoforms. As a 413 
result, p210 would encounter another subset of the proteome than p190 and 414 
would consequently differentially activate signaling pathways due to different 415 
interacting proteins, including kinases and phosphatases, ultimately resulting in 416 
pronounced differences in the phosphoproteome. In line with this hypothesis, 417 
deletion of the F-actin binding domain in p210 and p190 was found to have 418 
different effects on the leukemogenicity of Bcr-Abl29,30,31. In addition, the 419 
presence of the largely uncharacterized PH domain in p210 may play an 420 
important role in differential subcellular localization. PH domains are classical 421 
phosphoinositide-binding domains and mediate targeting of PH-domain 422 
containing proteins to membranes. If the p210 PH domain is important for Bcr-423 
Abl localization, however, needs to be clarified by future studies. Similarly, we 424 
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found that the AP2 adaptor protein complex and associated proteins strongly and 425 
preferentially interact with p190 (Fig. 7). The tetrameric AP2 complex mediates 426 
the internalization of membrane receptors by regulating the assembly of clathrin-427 
coated pits resulting in endocytosis. The functional consequences of the 428 
'hijacking' of the AP2 complex on Bcr-Abl localization or receptor trafficking in 429 
p190 cells warrant in-depth future analysis. Among the strongest differential 430 
interactors of p210, we found the non-canonical tyrosine phosphatase Sts-1, 431 
which was described as a negative regulator of the Zap-70 tyrosine kinases in T-432 
cell receptor signaling32. It is tempting to speculate that its strong interaction with 433 
p210 might be a mechanism to negatively regulate Bcr-Abl (Fig. 7). 434 
Among the strongest up-regulated phosphorylation events in p210 was Stat5 on 435 
6 tyrosine phosphorylation sites, including the major site that activates Stat5 436 
dimerization, nuclear translocation and transcriptional activation (Fig. 7). 437 
Importantly, Stat5 is an essential Achilles heel in CML, as it is absolutely 438 
required for disease initiation, as well as disease maintenance and Stat5 439 
upregulation mediates TKI resistance33,34. Interestingly, the strong activation of 440 
Stat5 by p210 but not p190 is mirrored by our previous data on the requirement 441 
of the upstream JAK2 kinase for initial lymphoid transformation by p190 (or v-Abl) 442 
but not myeloid transformation by p21013. These findings have important obvious 443 
implications for the ongoing studies of Jak2 TKIs in Ph-positive leukemias. 444 
Another critical class of downstream signaling mediators of Bcr-Abl are the Src 445 
kinases. We found that the Src family kinase Lyn and its interactor Hcls1 446 
(hematopoietic cell-specific Lyn substrate 1) show stronger interactions with 447 
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p190 than p210 and that Lyn further shows stronger phosphorylation in p190 448 
cells at 6 sites, including the activation loop (Fig. 7). Lyn, along with Hck and Fgr, 449 
was shown to be required for B-lymphoid, but not myeloid transformation35. Lyn 450 
upregulation was shown to mediate imatinib resistance36, and lymphoid, but not 451 
myeloid blast crisis CML cells are strongly dependent on Lyn expression and 452 
activity37. Similarly, the Fes tyrosine kinase that we found activated by p210 was 453 
previously shown to drive myeloid differentiation in K562 cells38. 454 
Collectively, these examples show that the mapped differential activation of 455 
tyrosine kinase and phosphatase pathways may indeed be tightly associated or 456 
causal to drive either myeloid or B-lymphoid transformation by p210 or p190. 457 
Finally, these kinases are readily druggable targets that may help patients to 458 
better cope with TKI resistance and offer more effective treatment options, 459 
particularly for Ph-positive B-ALL patients. 460 
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Figure legends 590 
Figure 1. Bcr-Abl domain organization and workflow of the proteomics 591 
experiments. 592 
(a) The Abl tyrosine kinase and the two isoforms of the fusion protein Bcr-Abl, 593 
p210 and p190, are shown with their sizes and domain arrangement. The p210 594 
isoform is 501 amino acids longer than p190 as it contains the DH-PH tandem 595 
domains. Domain abbreviations: CC: coiled-coil, DH: Dbl-homology, PH: 596 
Pleckstrin-homolgy, SH3/SH2: Src-homology 3/2, FABD: F-actin binding domain. 597 
(b) SILAC labeling was employed to allow quantitative comparison of three BaF3 598 
cell lines (Supplementary Table S1). BaF3 parental cells express Abl 599 
endogenously. BaF3 p210 and BaF3 p190 cells express human Bcr-Abl p210 600 
and p190. An immuno-affinity purification strategy was used to enrich for Bcr-Abl 601 
complexes for the interactome analysis and sample mixing was performed just 602 
prior peptide preparation. For analysis of the tyrosine phosphoproteome cell 603 
lysates were mixed prior enrichment of the pY peptides using the pY1000 and 604 
4G10 antibodies and an additional TiO2 purification step. For both experiments, 605 
the analysis of the total proteome served for different normalization steps. 606 
 607 
Figure 2. Analysis of the Bcr-Abl p210 and p190 interactome. 608 
(a) Quality control anti-Abl immunoblot after immuno-affinity purification of the 609 
Bcr-Abl complexes for a representative experiment. For the lysate samples 50 µg 610 
of total protein was loaded and an equivalent volume was used for the unbound 611 
fraction. The ratio of the two Bcr-Abl isoforms p210:p190 was 1.4:1 in the eluate, 612 
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which was in accordance with the quantification by mass spectrometry 613 
(Supplementary Fig. S1). For the elution fraction, 0.7% of the total SILAC eluate 614 
was loaded and quantification of bands enabled the calculation of the IP 615 
efficiency/Bcr-Abl complex recovery of 29% of the input amount. 616 
(b) Schematic representation of filtering criteria to select the differential Bcr-Abl 617 
interactors. Quantified proteins (1888 and 3767 proteins, respectively) were 618 
normalized to their input amounts (4066 and 3989 proteins quantified, 619 
respectively) and only those proteins with significant enrichment (according to 620 
Significance B) over the parental control were selected. This reduced number of 621 
proteins were further normalized for the Bcr-Abl IP amounts and finally selected 622 
if differentially enriched by at least 2-fold. A detailed description of the data 623 
analysis workflow is described in the Supplementary Methods. 624 
(c) Scatter plot representation depicting the final list of 147 Bcr-Abl interactors 625 
(58 common, 59 p190 enriched, 30 p210 enriched; see panel (b)) with the 626 
respective log2 ratios in both experiments (Bcr-Abl (BA) IP1 and IP2) showing an 627 
overall good correlation (R=0,72). Those proteins considered differential are 628 
colored in red (p210) and blue (p190). Selected proteins are highlighted with 629 
bigger dot size and gene name labels. 630 
(d) Validation of differential Bcr-Abl interactors by immunoblotting. Elution 631 
fractions of both replicates were analyzed corresponding to 0.7% of the total 632 
SILAC elution fraction. We chose to validate the interactome hits Ubash3B/Sts-1 633 
(enriched in p210) and AP2a1/2 and Lyn (both enriched in p190). The quantified 634 
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signal after correction for the Bcr-Abl IP amounts is shown on the right side. 635 
Individual values are plotted together with the mean +/- SD. 636 
 637 
Figure 3. Network of Bcr-Abl interacting proteins. 638 
Common and differential interactors of Bcr-Abl p210 and p190 are shown and 639 
summarized in Supplementary Tables S4 and S5. Connections for the differential 640 
interactors are color-coded according to their log2 ratios (from ‘light red’ for a 641 
weak p210 enrichment, to ‘dark red’ for a strong p210 enrichment; ‘light blue’ for 642 
a weak p190 enrichment to ‘dark blue’ for a strong p190 enrichment). Boxes 643 
around the individual proteins are color-coded according to the function and a 644 
red frame indicates that the protein was also found phosphorylated in the 645 
phosphoproteome analysis. Note that certain proteins enriched with either of the 646 
two Bcr-Abl isoforms can also interact with the other isoform and thus have a 647 
connection to both proteins. 648 
 649 
Figure 4. Bcr-Abl p210 and p190 phosphorylation sites and kinase activity. 650 
(a) Several Bcr-Abl pY sites were quantified in our phosphoproteome dataset. 651 
The domain organization and location of the pY sites are shown and the sites are 652 
plotted together with their respective log2 ratio between p210/p190. Dots 653 
represent mean values +/- SD. 5 out of the 17 sites could only be quantified in 654 
one experiment. Residues are numbered according to the Bcr and Abl 1b protein 655 
numbering.  656 
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(b) Immunoblot analysis of the two autophosphorylation sites that are important 657 
for Abl catalytic activity: pY245 and pY412. Equal amounts of total cell lysates of 658 
the indicated BaF3 and human p210 and p190 expressing cell lines were loaded, 659 
immunoblotted with the indicated antibodies and quantified (see (c)). Note that 660 
only Bcr-Abl is phosphorylated on Y245 and Y412, while Abl is not or only very 661 
weakly phosphorylated on these sites. 662 
(c) Quantified pY245 and pY412 immunoblot signals (from panel (b)) after 663 
normalization to the total Bcr-Abl protein in BaF3 (left two graphs) or human cell 664 
lines (right two graphs) from two replicates. Individual values are plotted together 665 
with the mean +/- SD. 666 
(d) Bcr-Abl was immunoprecipitated from the indicated BaF3 and human p210 667 
and p190 cell lines and a radioactive in vitro kinase activity was performed 668 
measuring phosphotransfer to an optimal Abl substrate peptide. Each kinase 669 
assay was run in triplicate for each immunoprecipitate and the resulting 670 
averaged activity value was normalized to the Bcr-Abl amount determined by 671 
immunoblot analysis. The bar graph shows the mean +/- SD from three biological 672 
replicates. 673 
 674 
Figure 5. Bcr-Abl pY phosphoproteome. 675 
(a) Heatmap representation of the 817 quantified phosphosites and their 676 
respective ratios in the comparison of the three samples: BaF3 parental, BaF3 677 
p210 and BaF3 p190. The two biological replicates are plotted next to each other. 678 
The six clusters identified by unsupervised hierarchical clustering are highlighted. 679 
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(b) Scatter plot for the normalized log2 ratios between the p210 and p190 Bcr-680 
Abl samples (without correction for the total protein levels) in both biological 681 
replicates (pY1 and pY2). Each dot is representative of a phosphopeptide. Those 682 
pY sites considered as differential are colored in red (p210) and blue (p190). 683 
Selected phosphorylation sites are labeled. 684 
(c, d) Immunoblot validation of Stat5 pY694 using the BaF3 and human cell line 685 
panel. The quantified signals of two technical replicates were normalized to the 686 
total Stat5 protein and individual values are plotted together with the mean +/- 687 
SD. 688 
 689 
Figure 6. Selected phosphorylation events of p210 and p190 Bcr-Abl. 690 
A selection of differential and common Bcr-Abl phosphorylation sites that were 691 
found in the pY dataset is shown. The complete dataset is shown in 692 
Supplementary Table S6, S7 and S8. Boxes around the individual proteins are 693 
color-coded according to their function and a red frame indicates that a protein 694 
was also found in the interactome analysis. 695 
 696 
Figure 7. Model of differential signaling networks of p210 and p190 Bcr-Abl. 697 
The main differences in Bcr-Abl interactors and phosphorlyated proteins between 698 
p210 and p190 that we found, validated and discussed in this paper is 699 
summarized in this figure. As examples for common interactors/pY sites, the 700 
Ship2 phosphatase and the interaction of the Grb2/Sos complex with pY177 is 701 
shown. p210 shows stronger association with the Sts-1 phosphatase and higher 702 
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activation of the Stat5 transcription factor, as well as the Erk1/2 and Fyn/Lck 703 
kinases. p190 shows stronger association with the AP2 complex and clathrin, 704 
and higher activation of the Dok1 adaptor and the Lyn kinase. 705 







